Back to search results

RISE vs. Enhanced Care for Intimate Partner Violence

This study is for Veterans Health Administration (VHA) patients who have experienced intimate partner violence (IPV) in the past year. It compares two counseling approaches: RISE (Recovering from IPV through Strength and Empowerment), which involves up to eight personalized sessions, and advocacy-based Enhanced Care as Usual (ECAU), a single session offering support and resources. The goal is to see which approach is better at improving your self-confidence (self-efficacy) and overall health. To join, you must be an adult receiving care at an enrolled VHA site, have reported past-year IPV, and be able to give informed consent. The study is currently unclear about its recruitment status and plans to enroll 172 participants.

Study design
This study is an interventional trial comparing two behavioral interventions. It aims to enroll 172 participants.
What's involved
You would participate in either up to 8 counseling sessions for RISE, or a single 60-minute session for ECAU. Your intervention sessions would be recorded.
Compensation
Not stated in the trial record.
Follow-up
Your self-efficacy will be measured at baseline, 3 months, 6 months, 9 months, 12 months, and 15 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06906302

RISE Versus Advocacy-based Enhanced Care as Usual for Patients Experiencing IPV

Recruiting
NAAges 18+InterventionalTreatment
Boston University
~172 participants
Updated 2025-10-14 on ClinicalTrials.gov
What's tested:RISEAdvocacy-based ECAU

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Self-efficacy
Measured over Baseline, 3 months, 6 months. 9 months, 12 months, 15 months

Conditions

Intimate Partner Violence (IPV)

Explore related trials

Intimate Partner Violence

Where it's being run

3 sites across 3 states
Massachusetts1
Minnesota1
Pennsylvania1

Study leadership

  • Katherine M Iverson, PhD · PRINCIPAL_INVESTIGATOR · V Boston Healthcare System, BU CASchool Medicine Psychiatry
  • Melissa Dichter, PhD MSW · PRINCIPAL_INVESTIGATOR · VA Philadelphia Healthcare System

Who to contact

Katherine M Iverson, PhD
[email protected]
857-364-2066
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

patients receiving care at an enrolled site/affiliated Community-Based Outpatient Clinic (CBOC)
report experience of past-year physical, psychological, and/or sexual IPV on an established screening tool used to detect IPV in VHA, and
be able to provide informed consent including permission to have intervention sessions recorded

Exclusion

severe cognitive impairment,
suicide or homicide intent with a specific plan
untreated or unstable symptoms of mania or psychosis

What this trial measures

  • Self-efficacyBaseline, 3 months, 6 months. 9 months, 12 months, 15 months

    Self-efficacy will be assessed with the General Self-Efficacy Scale (GSES), a 10-item instrument with possible responses for each item from 1 to 4 where 1= Not at all true, 2= Hardly true, 3= Moderately true, and 4=Exactly true.Scores can range from 10 to 40 and higher scores indicate more self efficacy.